Current Oncology Reports

, Volume 12, Issue 2, pp 102–108

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

  • Susan A. J. Vaziri
  • Jenny Kim
  • Mahrukh K. Ganapathi
  • Ram Ganapathi
Article

Abstract

Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SNPs]) associated with treatment outcome and toxicity. Notably, identification of SNPs in VEGF associated with angiogenesis inhibitor treatment-induced hypertension and outcome provides exciting opportunities for personalized medicine to improve outcome and reduced toxicity with these novel TKIs.

Keywords

Angiogenesis Tyrosine kinase inhibitors Hypertension VEGF polymorphism Outcome Toxicity 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Folkman J: Angiogenesis. Annu Rev Med 2006, 57:1–8.CrossRefGoogle Scholar
  2. 2.
    Bhargava P: VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 2009, 297:R1–R5.PubMedGoogle Scholar
  3. 3.••
    DePrimo SE, Bello CL, Smeraglia J, et al.: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32–43. This informative article discusses circulating biomarkers in mRCC patients treated with sunitinib.Google Scholar
  4. 4.••
    Ebos JML, Lee CR, Christensen JG, et al.: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. PNAS 2007, 104:17069–17074. This article discusses possible tumor-independence of circulating proangiogenic factors during treatment with sunitinib.Google Scholar
  5. 5.
    Rini BI, Dror Michaelson M, Rosenberg JE, et al.: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743–3748.CrossRefPubMedGoogle Scholar
  6. 6.
    Feldman DR, Baum MS, Ginsberg MS, et al.: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432–1439.CrossRefPubMedGoogle Scholar
  7. 7.
    Sane DC, Anton L, Brosnihan B: Angiogenic growth factors and hypertension. Angiogenesis 2004, 7:193–201.CrossRefPubMedGoogle Scholar
  8. 8.
    Hood JD, Meininger CJ, Ziche M, et al.: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998, 274:H1054–H1058.PubMedGoogle Scholar
  9. 9.
    Horowitz JR, Rivard A, van der Zee R, et al.: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arterioscler Thromb Vasc Biol 1997, 17:2793–2800.PubMedGoogle Scholar
  10. 10.
    Ciuffetti G, Schillaci G, Innocente S, et al.: Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003, 21:2297–2303.CrossRefPubMedGoogle Scholar
  11. 11.
    Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427–434.CrossRefPubMedGoogle Scholar
  12. 12.
    Maitland ML, Moshier K, Imperial J, et al.: Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. J Clin Oncol 2006, 24:2035.Google Scholar
  13. 13.
    Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359: 378–390.CrossRefPubMedGoogle Scholar
  14. 14.
    Giordano FJ, Gerber HP, Williams SP, et al.: A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. PNAS 2001, 98:5780–5785.CrossRefPubMedGoogle Scholar
  15. 15.••
    Chu TF, Rupnick MA, Kerkela R, et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet Oncol 2007, 370:2011–2019. This article reviews TKI-associated cardiotoxicity.Google Scholar
  16. 16.
    Rixe O, Bukowski RM, Dror Michaelson M, et al.: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975–984.CrossRefPubMedGoogle Scholar
  17. 17.
    Eremina V, Sood M, Haigh J, et al.: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707–716.PubMedGoogle Scholar
  18. 18.
    Schrijvers BF, Flyvbjerg A, DeVrise AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004, 65:2003–2017.CrossRefPubMedGoogle Scholar
  19. 19.
    Eremina V, Jefferson JA, Kowalewska J, et al.: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129–1136.CrossRefPubMedGoogle Scholar
  20. 20.
    Barakat RK, Singh N, Lal R, et al.: Interstitial nephritis secondary to bevacizumab treatment in metastatic meiomyosarcoma. Ann Pharmacother 2007, 41:707–710.CrossRefPubMedGoogle Scholar
  21. 21.
    Frankie C, Leachier C, Medina J, et al.: Renal thrombosis microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007, 8:177–178.CrossRefGoogle Scholar
  22. 22.
    Roncone D, Sattskar A, Nadasdy T, et al.: Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract 2007, 3:287–293.CrossRefGoogle Scholar
  23. 23.
    Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124.Google Scholar
  24. 24.
    Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184–2191Google Scholar
  25. 25.
    McDermott DF, Soman JA, Gonzalez R, et al.: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J Clin Oncol 2008, 26:2178–2185.Google Scholar
  26. 26.
    Kawai Y, Sakano S, Korenaga Y, et al.: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007, 52:1147–1155.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim DH, Lee NY, Lee MH, et al.: Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol 2007, 140:71–79.PubMedGoogle Scholar
  28. 28.••
    Schneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in trial of paclitaxel compared with paclitaxel compared with pacitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 20:4672–4678. This publication provides important information on VEGF SNPs that are associated with outcome and toxicity in patients treated with bevacizumab.Google Scholar
  29. 29.
    Hsiao PJ, Lu MY, Chiang FY, et al.: Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol 2007, 195:265–270.CrossRefPubMedGoogle Scholar
  30. 30.
    Jacobs EJ, Feigelson HS, Bain EB, et al.: Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006, 8:R22.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhai R, Liu G, Asomaning K, et al.: Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008, 29:2330–2334.CrossRefPubMedGoogle Scholar
  32. 32.
    Cacev T, Loncar B, Seiwerth S, et al.: Vascular endothelial growth factor polymorphisms -1154G/A and -460C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol 2008, 27:569–574.CrossRefPubMedGoogle Scholar
  33. 33.
    Heist RS, Zhai R, Lui G, et al.: VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:856–862.CrossRefPubMedGoogle Scholar
  34. 34.
    Ricketts C, Zeegers MP, Lubinski J, et al.: Analysis of germline variants in CDH1, IGFBBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PloS One 2009, 4:e6037.CrossRefPubMedGoogle Scholar
  35. 35.
    Smerdel MP, Waldstrom M, Brandslund I, et al.: Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009, 19:578–584.PubMedGoogle Scholar
  36. 36.
    Garcia-Closas M, Malats N, Real FX, et al.: Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007, 3:e29.CrossRefPubMedGoogle Scholar
  37. 37.
    Bae SJ, Ahn DH, Hong SP, et al.: Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patient with stomach cancer. Yonsei Med J 2008, 29:783–791.CrossRefGoogle Scholar
  38. 38.
    Churchill AJ, Carter JG, Ramsden C, et al.: VEGF Polymorphisms are associated with severity of diabetic retinopathy. Invest Ophtalmol Vis Sci 2008, 49:3611–3616.CrossRefGoogle Scholar
  39. 39.
    Nakanishi K, Watanabe C: Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. Clin Chim Acta 2009, 402:171–175.CrossRefPubMedGoogle Scholar
  40. 40.
    Breunis WB, Biezeveld MH, Geissler J, et al.: Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum 2009, 54:1588–1594.CrossRefGoogle Scholar
  41. 41.
    Yuan Q, Zuo X, Jia J: Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer’s disease among northern Chinese Han. Neurosci Lett 2009, 457:133–136.CrossRefPubMedGoogle Scholar
  42. 42.
    Salvarani C, Boiardi L, Casali B, et al.: Vascular endothelial growth factor gene polymorphisms in Behcet’s disease. J Rheumatol 2004, 31:1785–1789.PubMedGoogle Scholar
  43. 43.
    Galazioz G, Papazoglou D, Tsikouras P, et al.: Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med 2009, 22:371–378.CrossRefGoogle Scholar
  44. 44.
    Lin LM, Wan L, Tsai YY, et al.: Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Opthalmol 2008, 145:1045–1051.CrossRefGoogle Scholar
  45. 45.
    Butt C, Lim S, Greenwood C, et al.: VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord 2007, 8:1.CrossRefPubMedGoogle Scholar
  46. 46.
    Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, et al.: A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005, 32:1737–1743.PubMedGoogle Scholar
  47. 47.
    Doi K, Noiri E, Nakao A, et al.: Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol 2006, 17:823–830.CrossRefPubMedGoogle Scholar
  48. 48.
    Pages G, Puyssegur J: Transcriptional regulation of the vascular endothelial growth factor gene—a concert of activating factors. Cardiovascular Res 2005, 65:564–573.CrossRefGoogle Scholar
  49. 49.
    Pander J, Gelderblom H, Guchelaar HJ: Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 2007, 12:1054–1060.CrossRefPubMedGoogle Scholar
  50. 50.
    Renner W, Kotschan S, Hoffmann, C, et al.: A common 936 C/T Mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000, 37:443–448.CrossRefPubMedGoogle Scholar
  51. 51.••
    Bastide A, Karaa K, Bornes S, et al.: An upstream open reading frame with in an IRES controls expression of specific VEGF-A isoform. Nucleic Acids Res 2008, 36:2434–2445. This article identifies a region in the 5′UTR of VEGF (IRESB) that is critical in the expression of a VEGF isoform. The -634G>C SNP occurs in this region. This paper highlights the complex level of regulation of VEGF expression at the transcription and translation levels.Google Scholar
  52. 52.
    Facemire CS, Nixon, AB, Griffiths R, et al.: Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009, 54:652–658.CrossRefPubMedGoogle Scholar
  53. 53.
    Kim JJ, Vaziri SA, Elson BI, et al.: VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 2009, 27:15s.CrossRefGoogle Scholar
  54. 54.
    Schultheis AM, Lurje G, Rhodes KE, et al.: Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Can Res 2008, 14:7554–7563.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Susan A. J. Vaziri
    • 1
  • Jenny Kim
    • 1
  • Mahrukh K. Ganapathi
    • 1
  • Ram Ganapathi
    • 1
  1. 1.Taussig Cancer Institute - R40Cleveland Clinic FoundationClevelandUSA

Personalised recommendations